Related references
Note: Only part of the references are listed.ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells
Andrey Fadeev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
Amanda B. Pilling et al.
Oncotarget (2018)
ALK Protein Expression Is Related to Neuroblastoma Aggressiveness But Is Not Independent Prognostic Factor
Ji Won Lee et al.
CANCER RESEARCH AND TREATMENT (2018)
First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium
Frank M. Balis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
Andrew C. Wood et al.
CLINICAL CANCER RESEARCH (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Multiple Acquired Resistance Mutations of the ALK Tyrosine Kinase Domain after Sequential Use of ALK Inhibitors
Hsin-Yi Wang et al.
Journal of Thoracic Oncology (2017)
Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk
Elizabeth S. Mo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALKF1174L Drug-Resistant Neuroblastoma Preclinical Models
Libo Zhang et al.
TRANSLATIONAL ONCOLOGY (2017)
Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models
Hui Qin Wang et al.
ELIFE (2017)
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial
Carl E. Allen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Stratification of patients with neuroblastoma for targeted ALK inhibitor therapy.
D. Weiser et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model
Jiaxiong Lu et al.
CANCER LETTERS (2017)
Genetic susceptibility to neuroblastoma
Vanessa P. Tolbert et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2017)
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma
Kateryna Krytska et al.
CLINICAL CANCER RESEARCH (2016)
ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
D. N. Debruyne et al.
ONCOGENE (2016)
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma
Nicole R. Infarinato et al.
CANCER DISCOVERY (2016)
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models
Sen Zhang et al.
CLINICAL CANCER RESEARCH (2016)
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
J. Guan et al.
DISEASE MODELS & MECHANISMS (2016)
Alectinib Dose Escalation Reinduces Central Nervous System Responses in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer Relapsing on Standard Dose Alectinib
Justin F. Gainor et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
Joachim T. Siaw et al.
ONCOTARGET (2016)
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome
Olivia M. Padovan-Merhar et al.
PLOS GENETICS (2016)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models
Helen Y. Zou et al.
CANCER CELL (2015)
Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis
Angela Bellini et al.
CLINICAL CANCER RESEARCH (2015)
FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Sean Khozin et al.
CLINICAL CANCER RESEARCH (2015)
Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations
Thomas F. Eleveld et al.
NATURE GENETICS (2015)
Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand-receptor interactions
Andrey V. Reshetnyak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX
David Clynes et al.
NATURE COMMUNICATIONS (2015)
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Jikui Guan et al.
ELIFE (2015)
Intragenic Anaplastic Lymphoma Kinase (ALK) Rearrangements: Translocations as a Novel Mechanism of ALK Activation in Neuroblastoma Tumors
Susanne Fransson et al.
GENES CHROMOSOMES & CANCER (2015)
Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma
Fei Xu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
Cheng Ji et al.
CANCER BIOLOGY & THERAPY (2014)
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
Scott C. Bresler et al.
CANCER CELL (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Emergence of New ALK Mutations at Relapse of Neuroblastoma
Gudrun Schleiermacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Identification of a Novel HIP1-ALK Fusion Variant in Non-Small-Cell Lung Cancer (NSCLC) and Discovery of ALK I1171 (I1171N/S) Mutations in Two ALK-Rearranged NSCLC Patients with Resistance to Alectinib
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M. Lovly et al.
NATURE MEDICINE (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer REPLY
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteome
Hongbing Zhang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma
Ganesh Umapathy et al.
SCIENCE SIGNALING (2014)
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non-Small Cell Lung Cancer
Luc Friboulet et al.
CANCER DISCOVERY (2014)
Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
Nathan F. Moore et al.
ONCOTARGET (2014)
Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma
Alex Cazes et al.
CANCER RESEARCH (2013)
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma
Damini Chand et al.
DISEASE MODELS & MECHANISMS (2013)
ALK amplification and protein expression predict inferior prognosis in neuroblastomas
Miao Wang et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells
Kamaraj Sattu et al.
FEBS JOURNAL (2013)
Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration
Floor A. M. Duijkers et al.
GENE (2013)
Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants
Fiona K. E. McDuff et al.
MOLECULAR CARCINOGENESIS (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma
Mark Sausen et al.
NATURE GENETICS (2013)
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh et al.
NATURE GENETICS (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
Julie R. Park et al.
PEDIATRIC BLOOD & CANCER (2013)
High Anaplastic Lymphoma Kinase Immunohistochemical Staining in Neuroblastoma and Ganglioneuroblastoma Is an Independent Predictor of Poor Outcome
Floor A. M. Duijkers et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma
Teeara Berry et al.
CANCER CELL (2012)
Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis
Shizhen Zhu et al.
CANCER CELL (2012)
Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Tadaaki Yamada et al.
CLINICAL CANCER RESEARCH (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma
Nai-Kong V. Cheung et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase
Linda F. Epstein et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes
Jan J. Molenaar et al.
NATURE (2012)
Treating ALK-positive lung cancer-early successes and future challenges
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Targeting ALK in neuroblastoma-preclinical and clinical advancements
Erica L. Carpenter et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
E. L. Carpenter et al.
ONCOGENE (2012)
Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma
J. Okubo et al.
ONCOGENE (2012)
Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells
C. Schonerr et al.
ONCOGENE (2012)
Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres
Kylie Bower et al.
PLOS ONE (2012)
Targeted Expression of Mutated ALK Induces Neuroblastoma in Transgenic Mice
Lukas C. Heukamp et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Ryohei Katayama et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684
Christina Schonherr et al.
BIOCHEMICAL JOURNAL (2011)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Appearance of the Novel Activating F1174S ALK Mutation in Neuroblastoma Correlates with Aggressive Tumor Progression and Unresponsiveness to Therapy
Tommy Martinsson et al.
CANCER RESEARCH (2011)
High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Johannes H. Schulte et al.
CLINICAL CANCER RESEARCH (2011)
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Johannes M. Heuckmann et al.
CLINICAL CANCER RESEARCH (2011)
Genome-Wide Linkage Analysis to Identify Genetic Modifiers of ALK Mutation Penetrance in Familial Neuroblastoma
Marcella Devoto et al.
HUMAN HEREDITY (2011)
Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer
Marta Salido et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw et al.
LANCET ONCOLOGY (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo
Christina Schonherr et al.
TRANSLATIONAL ONCOLOGY (2011)
Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels
Floor A. M. Duijkers et al.
CELLULAR ONCOLOGY (2011)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification
Sara De Brouwer et al.
CLINICAL CANCER RESEARCH (2010)
Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century
Malcolm A. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung Cancer
Eunice L. Kwak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma Patients
Lorena Passoni et al.
CANCER RESEARCH (2009)
ALK (Anaplastic Lymphoma Kinase) expression in DRG neurons and its involvement in neuron-Schwann cells interaction
Joffrey Degoutin et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Copy number variation at 1q21.1 associated with neuroblastoma
Sharon J. Diskin et al.
NATURE (2009)
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
Helena Caren et al.
BIOCHEMICAL JOURNAL (2008)
Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George et al.
NATURE (2008)
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
John M. Maris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Fetal and neonatal neuroblastoma: Retrospective review of 271 cases
Hart Isaacs
FETAL AND PEDIATRIC PATHOLOGY (2007)
Neuroblastoma incidence and survival in European children (1978-1997): Report from the Automated Childhood Cancer Information System Project
Claudia Spix et al.
EUROPEAN JOURNAL OF CANCER (2006)
Characterization of the expression of the ALK receptor tyrosine kinase in mice
E Vernersson et al.
GENE EXPRESSION PATTERNS (2006)
Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells
JY Gouzi et al.
JOURNAL OF CELL SCIENCE (2005)
Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin
C Moog-Lutz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Biological role of anaplastic lymphoma kinase in neuroblastoma
Y Osajima-Hakomori et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma
D Trochet et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2004)
Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma
HM Amin et al.
ONCOGENE (2004)
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
A Motegi et al.
JOURNAL OF CELL SCIENCE (2004)
Neuroblastoma: Biological insights into a clinical enigma
GM Brodeur
NATURE REVIEWS CANCER (2003)
Activation of anaplastic lymphoma kinase is responsible for hyperphosphorylation of ShcC in neuroblastoma cell lines
I Miyake et al.
ONCOGENE (2002)
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
WG Dirks et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells
G Piccinini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway
B Souttou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Expression of the ALK tyrosine kinase gene in neuroblastoma
L Lamant et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
